Browsing by Author "Gómez-Llonín, Andrea"

Sort by: Order: Results:

  • Minimal residual disease, metastasis and immunity
    Badia-Ramentol, Jordi; Linares Aceituno, Jenniffer Lissethe; Gómez-Llonín, Andrea; Calon, Alexandre (MDPI, 2021)
    Progression from localized to metastatic disease requires cancer cells spreading to distant organs through the bloodstream. Only a small proportion of these circulating tumor cells (CTCs) survives dissemination due to ...
  • NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1/S transition and specific cyclin overexpression. Preclinical ground for targeted inhibition
    Carrillo-Tornel, Salvador; Chen-Liang, Tzu Hua; Zurdo, María; Puiggros Metje, Anna Maria; Gómez-Llonín, Andrea; García-Malo, María Dolores; Cuenca-Zamora, Ernesto José; Ortuño, Francisco José; Hurtado López, Ana María; Espinet Solà, Blanca; Jerez, Andrés (Wiley, 2022)
    Studies prior to next-generation sequencing (NGS) showed that the frequent indolent course of chronic lymphocytic leukaemia (CLL) is related to most cells remaining quiescent in the G0 -G1 cell cycle phase, due to the ...
  • Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL
    Blanco Ares, Gonzalo, 1989-; Vardi, Anna; Puiggros Metje, Anna Maria; Gómez-Llonín, Andrea; Muro, Manuel; Rodríguez-Rivera, María; Stalika, Evangelia; Abella Monreal, Eugenia; Gimeno Vázquez, Eva; López-Sánchez, Manuela; Senín Magan, Maria Alicia; Calvo, Xavier; Abrisqueta, Pau; Bosch José, Francesc Xavier, 1947-; Ferrer Del Alamo, Ana; Stamatopoulos, Kostas; Espinet Solà, Blanca (Taylor & Francis, 2018)
    Analysis of the T cell receptor (TR) repertoire of chronic lymphocytic leukemia-like monoclonal B cell lymphocytosis (CLL-like MBL) and early stage CLL is relevant for understanding the dynamic interaction of expanded B ...
  • Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors
    Rivas, Elisa; Linares Aceituno, Jenniffer Lissethe; Zwick, Melissa; Gómez-Llonín, Andrea; Guiu, Marc; Labernadie, Anna; Badia-Ramentol, Jordi; Lladó, Anna; Bardia, Lídia; Pérez-Núñez, Iván; Martínez-Ciarpaglini, Carolina; Tarazona, Noelia; Sallent-Aragay, Anna; Garrido, Marta; Celià-Terrassa, Toni; Burgués, Octavio; Gomis, Roger R.; Albanell Mestres, Joan; Calon, Alexandre (Nature Research, 2022)
    About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment. Here, we conduct a detailed analysis of two ...